Nationwide Children's Hospital
nationwidechildrens.orgTotal trials
229
Active
49
Phase 3
20
Total enrollment
34,833
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 41 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Anakinra | — | — | — | — | — | 1 | |
| Bridging Chemotherapy | — | — | — | — | — | 1 | |
| Induction Cycles A1-A3 | — | — | — | — | — | 1 | |
| Induction Cycles A4-5 | — | — | — | — | — | 1 | |
| Consolidation Cycle A6 | — | — | — | — | — | 1 | |
| HIT-SKK Chemotherapy Cycles B1-3 | — | — | — | — | — | 1 | |
| Modified HIT-SKK Cycle B4-5 | — | — | — | — | — | 1 | |
| Temozolomide | — | — | — | — | — | 3 | |
| Cabozantinib | — | — | — | — | — | 1 | |
| Tissue Engineered Vascular Grafts | — | — | — | — | — | 1 | |
| Ribociclib | — | — | — | — | — | 1 | |
| Everolimus | — | — | — | — | — | 1 | |
| Tovorafenib | — | — | — | — | — | 1 | |
| Tocilizumab | — | — | — | — | — | 1 | |
| PEP-CMV | — | — | — | — | — | 1 | |
| Tetanus Diphtheria Vaccine | — | — | — | — | — | 1 | |
| GEM/DOX + TGFBi expanded NK cells | — | — | — | — | — | 1 | |
| Universal donor derived CD33 CAR-NK | — | — | — | — | — | 1 | |
| LUTATHERA® | — | — | — | — | — | 1 | |
| Natural Killer Cells | — | — | — | — | — | 1 | |
| Irinotecan | — | — | — | — | — | 1 | |
| Dinutuximab | — | — | — | — | — | 1 | |
| Sargramostim | — | — | — | — | — | 1 | |
| Adenovirus Specific T lymphocytes | — | — | — | — | — | 1 | |
| Universal Donor Natural Killer Cells | — | — | — | — | — | 1 | |
| ACT001 | — | — | — | — | — | 1 | |
| scAAV1.tMCK.NTF3 | — | — | — | — | — | 1 | |
| MIBG | — | — | — | — | — | 1 | |
| Binimetinib Oral Tablet [Mektovi] | — | — | — | — | — | 1 | |
| PTC596 | — | — | — | — | — | 1 | |
| NK cells | — | — | — | — | — | 1 | |
| CD19 specific Chimeric Antigen Receptor T Cell | — | — | — | — | — | 1 | |
| Larotrectinib | — | — | — | — | — | 1 | |
| Lorlatinib | — | — | — | — | — | 1 | |
| Lorlatinib with chemotherapy1 | — | — | — | — | — | 1 | |
| Lorlatinib with chemotherapy 2 | — | — | — | — | — | 1 | |
| Lorlatinib post Radiation | — | — | — | — | — | 1 | |
| Responsive Management Intervention | — | — | — | — | — | 1 | |
| Omeprazole | — | — | — | — | — | 1 | |
| Genetic characterization | — | — | — | — | — | 1 |
1 more active programs hidden
Next readouts
- 2024-03-01
- 2025-12-31
- 2026-02-28
- 2026-07
- 2026-08
- 2026-10-01
- 2026-12
- 2026-12-01
- 2026-12-01
- 2027-02
Top conditions
- High Grade Glioma9
- Burns7
- Diffuse Intrinsic Pontine Glioma7
- Surgery7
- Low Back Pain5
- Acute Pain5
- Procedural Pain4
- Pain4
Frequently asked questions about Nationwide Children's Hospital
- How many clinical trials does Nationwide Children's Hospital have on ClinicalTrials.gov?
- Nationwide Children's Hospital is listed as the lead sponsor on 229 clinical trials in ClinicalTrials.gov, 49 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Nationwide Children's Hospital's trials are in Phase 3?
- 20 of Nationwide Children's Hospital's trials are in Phase 3, spread across 41 active drug programs.
- What therapeutic areas does Nationwide Children's Hospital focus on?
- Nationwide Children's Hospital's most-studied conditions on ClinicalTrials.gov are High Grade Glioma, Burns, Diffuse Intrinsic Pontine Glioma, Surgery, Low Back Pain.
- When are Nationwide Children's Hospital's next clinical trial readouts?
- Nationwide Children's Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma”, expected around 2024-03-01.